Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
INVA
Strong BuyFLAGInnoviva, Inc. · Healthcare · United States · $1.5B · Avg Vol: $14M/d
Innoviva collects royalties on respiratory drugs, an attractive cash stream, but management has been redeploying that cash into acquired commercial assets and a convertible-financed balance sheet rather than pure distribution. That capital-allocation shift makes forward economics harder to underwrite than the royalty base alone suggests. No fraud or distress event is known, so this is a flag rather than a removal.
COMPANY DESCRIPTION
Innoviva, Inc. focuses on royalties from respiratory drugs, primarily through its collaboration with GlaxoSmithKline (GSK) on therapies like Relvar/Breo Ellipta and Anoro Ellipta. The company benefits from a stable, long-term revenue stream derived from royalties on blockbuster respiratory medications, minimizing operational and R&D expenditures. It is a unique healthcare company acting primarily as a royalty aggregator, providing exposure to established drug franchises.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.3M | 310.5M | 358.7M | 411.3M | 7.5% | 440.0M | 446.5M | 488.7M | 9.0% |
| EPS | 3.07 | 2.75 | 0.37 | 4.02 | 9.4% | 4.31 | 4.10 | 4.74 | 8.6% |
| Shares | 69.2M | 63.3M | 62.7M | 74.6M | +7.9% | 72.2M | — | — | — |
| Debt | 544.1M | 449.1M | 451.1M | 269.0M | -20.9% | 331.2M | — | — | — |
| Equity | 565.8M | 675.0M | 691.2M | 1.2B | 27.5% | — | — | — | — |
| Op CF | 201.7M | 141.1M | 188.7M | 196.9M | -0.8% | 191.5M | — | — | — |
| Inv CF | -56.6M | -66.8M | -63.8M | 40.5M | — | — | — | — | — |
| Fin CF | -55.6M | -171.8M | -13.5M | 8.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INVA | Innoviva, Inc.(you) | $1.5B | 93 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 87 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $1.3B | 71 | Buy |
| FTRE | Fortrea Holdings Inc. | $1.8B | 70 | Buy |
| PBYI | Puma Biotechnology, Inc. | $468M | 99 | Strong Buy |
| QTTB | Q32 Bio Inc. | $447M | 88 | Strong Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.7%